Cambridge, Mass.-based Akcea Therapeutics priced its offering of 15.6 million shares at $8 apiece to reach its $125 million IPO target. The company initially priced an offering of 9.6 million shares at $12 to $14 per share.
Akcea’s shares are slated to begin trading on the Nasdaq exchange today under the “AKCA.”
Get the full story at our sister site, Drug Delivery Business News.